Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Lyra Therapeutics, Inc. (LYRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline Results from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Now Anticipated Earlier Than Expected, in September 2023 -- WATERTOWN, Mass., August 8, 2023 -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis , today reported its financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Lyra is approaching two exciting clinical milestones: We ex..."
05/12/2023 8-K Quarterly results
Docs: "Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- WATERTOWN, Mass., May 12, 2023 -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis , today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We've had a highly productive start to 2023, positioning us for anticipated key data readouts over the next 12 months,” said Maria Palasis, Ph.D., Pre..."
11/08/2022 8-K Quarterly results
Docs: "Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update -- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis ; Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture All Clinical Trial Supply to Leverage its In-House Expertise and Capabilities; Temporarily Pausing Enrollment in ENLIGHTEN II Trial of LYR-210 in CRS to Align with Manufacturing Timelines; Enrollment Expected to Resume in the Third Quarter of 2023 -- WATERTOWN, Mass., November 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing novel, integrated drug and delivery solutions for the localized treatment of patients with chronic rhinosinusitis , today reported its fi..."
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024"
03/09/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update - LYR-210 Phase 3 ENLIGHTEN and LYR-220 Phase 2 BEACON studies on track to initiate around EOY - -"
05/11/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "LYRA THERAPEUTICS, INC."
08/05/2020 8-K Quarterly results
05/28/2020 8-K Quarterly results
Docs: "Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update WATERTOWN, MA - May 28, 2020 - Lyra Therapeutics, Inc. , a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today reported financial results for the quarter ended March 31, 2020 and provided a corporate update. Key First Quarter 2020 and Subsequent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy